Psilocybin may directly target Alzheimer’s disease mechanisms by reducing neuroinflammation, promoting neuroplasticity, and potentially slowing cognitive decline

Psilocybin is being framed as a potential treatment that could act on the underlying biology of Alzheimer’s disease rather than only easing symptoms. The central claim links psilocybin to reduced neuroinflammation, improved neural connectivity, and increased neuroplasticity, all of which are relevant to memory loss and cognitive decline. Alzheimer’s disease is commonly associated with amyloid plaques, tau pathology, chronic inflammation, and the breakdown of communication between brain regions. Psilocybin’s activity at serotonin receptors, especially 5-HT2A, is presented as a possible route to modulate these processes and support brain repair mechanisms. That framing matters because current Alzheimer’s drugs often deliver limited symptomatic benefit or narrowly target one pathway. Psilocybin is positioned here as part of a broader shift toward therapies that address inflammation, connectivity, and systems-level brain function, although strong clinical proof in Alzheimer’s patients still appears limited.